CVCamille P. Vaughan

Camille P. Vaughan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Camille P. Vaughan has a total of 338 co-authors. Here are the top co-authors by number of shared publications:

  • Theodore M. Johnson

    Birmingham/Atlanta Geriatric Research Education and Clinical Center, US Department of Veterans Affairs, Atlanta, Georgia

    13 shared publications
  • Alayne D. Markland

    Division of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City, UT; Geriatric Research, Education, and Clinical Center at the Birmingham Veterans Affairs Health Care System; Birmingham, AL

    9 shared publications
  • Gerald McGwin

    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham

    8 shared publications
  • Alayne D. Markland

    Division of Geriatrics, Department of Internal Medicine, University of Utah, Salt Lake City

    7 shared publications
  • Kathryn L. Burgio

    5 shared publications
  • Sara Turbow

    Division of General Internal Medicine, Department of Medicine Emory University School of Medicine Atlanta Georgia USA

    5 shared publications

Latest Publications

  • Consensus expert recommendations for management of urinary dysfunction in Parkinson disease

    by Delaram Safarpour, Camille P. Vaughan, Kathleen E. McKee, Alexandra L. Tabakin, Pinky Agarwal, Aditya V. Boddu, Frank C. Lin, Hillary A. Williams, Javier E. Santiago, Jun Song, et al.


  • Sleep Health, Perceived Stress, and Urinary Incontinence Severity Among Women Veterans in the USA

    by Danielle Scharp, Karen M. Goldstein, Camille P. Vaughan, Constance Fung, Orna Intrator, Alayne D. Markland

  • Associations between psychological and trauma-related factors and urinary incontinence severity and treatment response among women veterans

    by Danielle Scharp, Karen M. Goldstein, Ursula A. Kelly, Kathryn L. Burgio, Camille P. Vaughan, Orna Intrator, Alayne D. Markland


  • Open Access

    Optimizing remote access to Urinary Incontinence Treatments for Women Veterans: Identifying salient features of participants’ experiences with two delivery modalities

    by Beverly R. Williams, Kathryn L. Burgio, Katharina V. Echt, Karen M. Goldstein, Camille P. Vaughan, Ursula Kelly, Alayne D. Markland

  • Open Access

    Better than nothing, far from perfect: hospital and healthcare system leaders’ perspectives on health information exchanges

    by Sara D Turbow, Camille P Vaughan, Mohammed K Ali, Carolyn K Clevenger, Molly M Perkins

    Objectives: Implementation and effective use of health information exchange (HIE) has the potential to transform health care and improve patient outcomes across the United States, yet HIEs remain underutilized nationally. The goal of this study was to develop an updated understanding of current barriers and facilitators to HIE implementation, adoption, and use from the perspective of hospital and healthcare leaders. Materials and Methods: Using semistructured interviews, hospital and healthcare leaders were recruited from 7 healthcare systems in Atlanta, GA. Recruitment ceased when saturation was reached. Interviews focused on current use of HIE at hospitals/healthcare systems, beliefs about the value of HIE to patients, clinicians, and health systems, barriers and facilitators of HIE implementation and use, and where HIE should go in the future. Thematic analysis was used to develop codes and group them into final themes. Results: Interviews were conducted with 20 hospital and healthcare system leaders; all hospitals used the same enterprise HIE, while some also participated in the state HIE or other HIEs. Five key themes were identified: HIEs are better than nothing, HIEs are far from perfect, policy determines HIE efficacy and useability, technological challenges, and future directions. Key subthemes included HIE-benefit patients/the health system; tensions between customization and standardization; system-/end-user-level barriers; patient understanding of HIE; government, institutional, and vendor policies; and data quality, security, and technological/training capacity. Conclusion: Participants identified numerous barriers that decrease the effectiveness of HIE, some of which are modifiable. As HIE becomes more widely available, attention must shift toward addressing the barriers and understanding the facilitators of HIE use at the point of care, rather than HIE implementation.


  • Evaluating the effectiveness of a telemedicine-based STEADI implementation in primary care on fall outcomes: the STEADI options randomized controlled trial

    by Yara K Haddad, Matthew W Brault, Briana Moreland, Cora Peterson, Xinjian Zhang, Karen Thomas, Farah Sublett, Michelle Dougherty, Laurie Imhof, Madeleine E Hackney, et al.

    Background and Objectives: Falls are a leading cause of injury and death among older adults (65 years and above). The Centers for Disease Control and Prevention’s Stopping Elderly Accident, Deaths, and Injuries (STEADI) initiative aims to reduce falls by screening to find at-risk individuals, evaluation, and then addressing modifiable risk factors. This study evaluated the effectiveness of implementing a STEADI-based multi-component fall prevention approach via telemedicine in primary care. Research Design and Methods: A randomized controlled quality improvement trial (STEADI Options) was conducted during the COVID-19 pandemic (July 2020–December 2021). Primary care professionals (PCPs) were randomized to either standard-of-care (SOC) or intervention. The intervention included a fall risk assessment by a research nurse, who shared STEADI-based recommendations with PCPs. Recommended interventions were administered at the discretion of PCPs. Outcomes included self-reported falls (primary), medically treated falls, fall-related service utilization (physical therapy, occupational therapy, eye care, podiatry), and medication changes, assessed over one year. Analyses followed an intent-to-treat approach. Results: Among 660 participants (353 SOC; 307 intervention), the cohort was predominantly female (67.7%), aged 65–79 years (73.6%), and non-Hispanic White (56.1%). Intervention participants had higher average Stay Independent Screener (SIS) scores (6.3 vs. 5.2; p < 0.001). Overall, 5.5% reported a fall in the past 12 months. No significant differences were observed between groups in fall-related outcomes (e.g., medically treated falls odds ratio [adjusted for SIS]: 0.741; 95% CI: 0.411–1.336). Discussion and Implications: Although no significant differences were found, limited recruitment, low baseline fall rates, and unmeasured adherence may have impacted results. Further research is needed to evaluate the feasibility and effectiveness of telemedicine-based STEADI interventions in primary care.


  • Open Access

    Association of Chronic Conditions With Bladder Health in Women: Cross-Sectional Results From the RISE FOR HEALTH Study

    by Camille P. Vaughan, Gerald McGwin, Jean F. Wyman, Siobhan Sutcliffe, Diane K. Newman, Ariana L. Smith, Colleen M. Fitzgerald, Todd Rockwood, James Griffith, Sheila Gahagan, et al.

    Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.


  • Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease

    by Camille P. Vaughan, James F. Morley, Jessica Lehosit, Gerald McGwin, Lisa Muirhead, Anjali Khakharia, Theodore M. Johnson, Marian L. Evatt, Taressa Sergent, Kathryn L. Burgio, et al.

    Importance: Overactive bladder (OAB) symptoms in Parkinson disease (PD) are burdensome, and the adverse effects of drug treatment can worsen PD-associated morbidity. Drug adverse effects are avoided with pelvic floor muscle exercise–based behavioral therapy.Objective: To assess the noninferiority of behavioral compared with solifenacin drug therapy for OAB symptoms in persons with PD.Design, Setting, and Participants: This 12-week randomized noninferiority trial of behavioral therapy compared with solifenacin was conducted between 2018 and 2023 within 4 US Veterans Affairs health care systems. Eligible participants were diagnosed with PD by a movement disorder neurologist and had an International Consultation on Incontinence Questionnaire OAB module (ICIQ-OAB) symptom score of 7 or higher (range, 0-16; higher score indicates worse symptoms) and Montreal Cognitive Assessment (MOCA) score of 18 or higher (range, 0-30). Participants were randomized 1:1 after stratification by sex, recruitment site, OAB severity, and PD motor symptom severity. Analyses were conducted from October 2023 to April 2024.Interventions: Behavioral therapy was implemented by a nurse practitioner and included pelvic floor muscle training and urge suppression strategies. Solifenacin therapy started at 5 mg daily, with titration to 10 mg daily if needed.Main Outcome and Measures: The primary outcome was the 12-week ICIQ-OAB score across groups within a 15% noninferiority margin. Adverse events were assessed every 2 weeks for 8 weeks and again at 12 weeks.Results: A total of 77 persons with PD (65 [84%] male; mean [SD] age, 71.3 [8.9] years; mean [SD] years with PD, 6.6 [5.8]) were randomized to behavioral (n = 36) or drug therapy (n = 41). Seventy-three participants completed the study (4 dropped out in drug group). Baseline characteristics were balanced across groups, including MOCA score (mean [SD], drug, 23.9 [3.1]; behavioral, 24.8 [3.3]) and ICIQ-OAB score (mean [SD], drug, 9.1 [1.7]; behavioral, 8.5 [1.4]). At 12 weeks postrandomization, ICIQ-OAB scores across groups indicated clinically significant improvement and were within the a priori noninferiority margin of 15% (mean [SD] score, drug, 5.8 [2.4]; behavioral, 5.5 [2.0]; P = .02). Dry mouth and falls were reported more frequently in the drug compared with the behavioral group.Conclusions and Relevance: Results of this randomized noninferiority trial suggest that behavioral therapy is noninferior to drug therapy in improving OAB symptoms in PD. These findings may inform clinical guidelines for urinary symptoms in PD to consider behavioral therapy as an initial treatment option.Trial Registration: ClinicalTrials.gov Identifier: NCT03149809


  • Association of menopausal status and hormone use with bladder health and lower urinary tract symptoms in US women: results from the RISE FOR HEALTH study

    by Camille P. Vaughan, Alayne D. Do Markland, Gerald McGwin, Emily S. Lukacz, Sonya S. PhD Brady, Yvette D. Lacoursiere, Jean F. Wyman, Siobhan PhD Sutcliffe, Ariana L. Smith, Kimberly Kenton, et al.

    Objectives: Most previous studies of genitourinary symptoms associated with menopause focus on comparisons of postmenopausal to premenopausal women and less is known about bladder health during menopause. We evaluated associations of menopause status and hormone use with bladder health and lower urinary tract symptoms (LUTS). Methods: Data were collected from May 2022 to December 2023 from a regionally representative cohort of community-dwelling adult women in the United States. Bladder health and LUTS were measured using validated questionnaires. Analyses included multivariable linear and logistic regression models. Results: Of 3,423 eligible participants, 3,126 responded to menopause and hormone use questions. Of these, 1,226 were premenopausal, 260 perimenopausal, and 1,640 postmenopausal. Premenopausal women reported hormone use more often than perimenopausal or postmenopausal women (38.3% vs. 21.5% and 13.2%). Across multiple bladder health scales (BHS, range 0-100) and bladder function indices (BFI, range 0-100), perimenopause and postmenopause status were associated with worse scores compared with premenopause status. Perimenopausal women were more likely to report urgency UI [OR 2.27, (95% CI: 1.49-3.46)] and other LUTS compared to premenopausal women. Hormone use was associated with worse bladder health in postmenopausal women [postmenopause/hormone −6.0 Overall BHS, (95% CI: −9.8 to −2.2)] and BFI [postmenopause/hormone BFI −4.8, (95% CI: −7.4 to −2.2)]. Conclusions: Promotion of bladder health and LUTS prevention is important as women approach the menopause transition. Hormone use was infrequently reported in perimenopausal and postmenopausal women and was associated with worse bladder health postmenopause.